Selenium status and lipid peroxides in patients with cardiovascular diseases

P. A. Lebedev

Kazan medical journal ›› 1995, Vol. 76 ›› Issue (4) : 332 -335.

PDF
Kazan medical journal ›› 1995, Vol. 76 ›› Issue (4) :332 -335. DOI: 10.17816/kazmj104975
Theoretical and clinical medicine
research-article

Selenium status and lipid peroxides in patients with cardiovascular diseases

Author information +
History +
PDF

Abstract

Selenium concentration in blood and plasma as well as the activity of glutathionperoxidase of erythrocytes and lipid peroxides are studied in patients with neurocirculatory dystonia, ischemic heart disease, hypertrophic and dilatation cardiomyopathy. The reduction of the activity of glutathioperoxidase of erythrocytes and activation of lipid peroxides without blood selenium concentration decrease are revealed in patients with neurocirculatory dystonia. The decrease of blood selenium concentration, the activity of glutathionperoxidase of erythrocytes and activation of lipid peroxides are revealed in patients with ischemic heart disease, dilatation and hypertrophic cardiomyopathy. The content of blood serum selenium is linked with lipid peroxides and magnitude of left ventricle diastolic dimension in patients with dilatation cardiomyopathy. The results obtained suggest selenium particilation in cardiomyopathy and ischemic heart disease pathogenesis aproving the study of selenium-containing drugs utility.

Keywords

Kazan Medical archive

Cite this article

Download citation ▾
P. A. Lebedev. Selenium status and lipid peroxides in patients with cardiovascular diseases. Kazan medical journal, 1995, 76(4): 332-335 DOI:10.17816/kazmj104975

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Гаврилов В. Б., Мешкорудная М. И.// Вопр. мед. химии,— 1983.— № 3,— С. 33—35

[2]

Гаврилова А. Р., Хмара Н. Ф.//Лабор. дело.— 1986.— № 12,— С. 721—724

[3]

Клебанов Г., Бабенкова И. В.//Лабор. дело.— 1988.— № 5,— С. 59

[4]

Коробейникова О. Н.//Лабор. дело.— 1989.— № 7.— С. 8—10

[5]

Кудрин А. Н. I Росссийский национальный конгресс «Человек и лекарство».— М., 1992.— С. 414

[6]

Ланкин В. З., Вихерт А. М.//Арх. патол.— 1989.— № 1.— С. 80—84

[7]

Bayfield R. F., Romalis L. F.//Analytical Biochem.— 1985.— Vol. 144.— P. 569—576

[8]

Huttunen J. K.//Acta Pharmacol. et Toxicol.— 1986.— Vol. 59.— Suppl 7.— P. 311—316

[9]

Moore J. A., Noiva R., Wells I. C.//Clin. Chem.— 1984.— Vol. 30.— P. 1171—1173

[10]

Oster O., Prellwitz W., Kasper W., Meinertz T.//Clin. Chim. Acta.— 1983.— Vol. 128.— P. 125—132

[11]

Pieban P. A., Muniani A., Beachum J.// Clin. Chem.— 1982,— Vol. 28,— P. 311—316

[12]

Popovici D.//Rev. Roum. Med.— Endocrinol.— 1987.— Vol. 25.— P. 191—196

[13]

Virtamo J., Huttunen J. K.//Ann. Clin. Res.— 1985,— Vol. 17.— P. 87—89

[14]

Winnefeld K., Dawczynski H., Bosseckert H., Kauf E. et al./Trace Elem. Med.— 1993,— Vol 10,— P. 90—92

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

194

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/